UMN Pharma Receives Investment From Tokyo Engineering Company
This article was originally published in PharmAsia News
Akita-based UMN Pharma signed a contract with Tokyo-based IHI Plant Engineering, which will design manufacturing equipment for UMN's new avian flu vaccine production plant in Akita Prefecture in early 2009. The total contract's estimated value is ¥2 billion. To strengthen the cooperation with UMN Pharma, IPEC invested ¥200 million and acquired 2 percent of UMN shares. IPEC also plans to further invest ¥200 million in the bioventure company. (Click here for more - Japanese language
You may also be interested in...
India clears Opdivo patent, turning down pre-grant representations from four opposing parties including Dr Reddy's. The patent office rejected the opponents' arguments including those around obviousness and "inherent anticipation."
BD Diagnostics has gained emergency use authorization (EUA) for a handheld rapid COVID-19 antigen test that could play a pivotal role in fighting an ongoing surge of coronavirus outbreaks. See what US FDA commissioner Stephen Hahn said about it here.
US government to own doses of Regeneron's investigational cocktail antibody REGN-COV2 manufactured under a $450m contract and 100 million doses of Novavax's investigational vaccine under a $1.6bn agreement.